A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Neurosciences Bookmark and Share

Neurosciences

Study of the nervous system has a long tradition at City of Hope, which was one of the first institutions in North America to establish a neurobiology research department.

The Department of Neurosciences offers a multidisciplinary research and training environment in neurobiology, with a particular focus on developmental aspects of the nervous system. Research in the department encompasses molecular and cellular neurobiology, genetics and neurophysiology, with ongoing studies in neurogenesis and synaptogenesis, migration and specification, degeneration and embryonic stem cell differentiation.

Researchers in the department collaborate with colleagues in other basic science departments and divisions as well as clinical researchers in neuro-oncology programs, focusing on cancer immunotherapy and neurosurgery.
 
Laboratory Research
The Department of Neurosciences spans a broad range of research interests; grouped into three major categories:

I.Several investigators are interested in the earliest periods of neurogenesis and lineage commitment, and are examining stem and progenitor cells in developing and mature brain:
 
  • Qiang Lu, Ph.D. – Neural Progenitor/Stem Cells in Brain Development
    Dr. Lu’s research is concerned with intercellular signaling by ephrins and Eph receptors and their regulation of neuronal birth and migration during early development of the cerebral cortex.
 
  • Yanhong Shi, Ph.D. – Nuclear Receptors in Neural Stem Cells and Adult Neurogenesis
    Dr. Shi is studying the nuclear receptors that control generation and differentiation of neural lineage stem cells in the adult nervous system.
 
  • Michael Barish, Ph.D. – Neurobiology of Development
    Dr. Barish is investigating early electrical activity in the developing hippocampus and cortex and its relationship to neural birth, migration and maturation.
     
  • Karen S. Aboody, M.D.Translational Research
    Dr. Aboody oversees a translational research laboratory focused on neural stem cells (NSCs) as a platform for targeted delivery of therapeutic agents to invasive and metastatic solid tumors.

II.Several faculty have research foci in neural specification, processes that impart individuality to developing neurons, and in the functioning of mature neurons.
 
  • Paul Salvaterra, Ph.D. – Molecular Neurobiology
    Dr. Salvaterra’s research is focused on the regulation of transmitter phenotype, how gene expression is coordinated to allow synthesis and release of individual neurotransmitters.
 
  • Toshifumi Tomoda, Ph.D. – Axonal Trafficking / Neurodegeneration
    Dr. Tomoda is interested in membrane transport and cycling, and its role in axon and dendrite growth, differentiation of synapses, and stress-induced autophagy.
 
  • Kazuo Ikeda, Ph.D. – Neurophysiology
    Dr. Ikeda studies the mechanisms of synaptic transmission and plasticity, focusing on endocytosis of synaptic vesicle membrane from presynaptic terminals and processes of recovery from vesicle depletion as a consequence of activity.

III.Several faculty members also have projects that relate their fundamental research interests to mechanisms underlying diseases of the human nervous system.
 
  • Dr. Salvaterra is developing Drosophila models for Alzheimer’s and other degenerative diseases.
     
  • Dr. Lu is examining how alteration in the neural stem cell decision to proliferate or differentiate controlled by ephrin/Eph receptor signaling may be involved in the earliest stages of tumorigenesis.
     
  • Dr. Tomoda is investigating possible connections between genes involved in membrane cycling and autophagy, and several diseases including Huntington’s and schizophrenia.
     
  • Dr. Barish, in collaboration with Karen Aboody, M.D. , (Hematology/HCT) and Carlotta Glackin, Ph.D. , is examining the molecular mechanisms of neural progenitor cell migration to glioma and tumors outside the brain, and targeting of these tumors with genetically-modified therapeutics using immortalized neural progenitor cells.
     
  • Dr. Glackin and her laboratory are investigating the molecular mechanisms of a bHLH transcription factor, TWIST, in regulating cellular invasiveness. Understanding these mechanisms has allowed her laboratory to develop novel genetically-modified therapeutics that interferes with TWIST function to competitively inhibit cellular invasion of tumor cells.

Neurosciences Faculty

Neurosciences

Neurosciences

Study of the nervous system has a long tradition at City of Hope, which was one of the first institutions in North America to establish a neurobiology research department.

The Department of Neurosciences offers a multidisciplinary research and training environment in neurobiology, with a particular focus on developmental aspects of the nervous system. Research in the department encompasses molecular and cellular neurobiology, genetics and neurophysiology, with ongoing studies in neurogenesis and synaptogenesis, migration and specification, degeneration and embryonic stem cell differentiation.

Researchers in the department collaborate with colleagues in other basic science departments and divisions as well as clinical researchers in neuro-oncology programs, focusing on cancer immunotherapy and neurosurgery.
 
Laboratory Research
The Department of Neurosciences spans a broad range of research interests; grouped into three major categories:

I.Several investigators are interested in the earliest periods of neurogenesis and lineage commitment, and are examining stem and progenitor cells in developing and mature brain:
 
  • Qiang Lu, Ph.D. – Neural Progenitor/Stem Cells in Brain Development
    Dr. Lu’s research is concerned with intercellular signaling by ephrins and Eph receptors and their regulation of neuronal birth and migration during early development of the cerebral cortex.
 
  • Yanhong Shi, Ph.D. – Nuclear Receptors in Neural Stem Cells and Adult Neurogenesis
    Dr. Shi is studying the nuclear receptors that control generation and differentiation of neural lineage stem cells in the adult nervous system.
 
  • Michael Barish, Ph.D. – Neurobiology of Development
    Dr. Barish is investigating early electrical activity in the developing hippocampus and cortex and its relationship to neural birth, migration and maturation.
     
  • Karen S. Aboody, M.D.Translational Research
    Dr. Aboody oversees a translational research laboratory focused on neural stem cells (NSCs) as a platform for targeted delivery of therapeutic agents to invasive and metastatic solid tumors.

II.Several faculty have research foci in neural specification, processes that impart individuality to developing neurons, and in the functioning of mature neurons.
 
  • Paul Salvaterra, Ph.D. – Molecular Neurobiology
    Dr. Salvaterra’s research is focused on the regulation of transmitter phenotype, how gene expression is coordinated to allow synthesis and release of individual neurotransmitters.
 
  • Toshifumi Tomoda, Ph.D. – Axonal Trafficking / Neurodegeneration
    Dr. Tomoda is interested in membrane transport and cycling, and its role in axon and dendrite growth, differentiation of synapses, and stress-induced autophagy.
 
  • Kazuo Ikeda, Ph.D. – Neurophysiology
    Dr. Ikeda studies the mechanisms of synaptic transmission and plasticity, focusing on endocytosis of synaptic vesicle membrane from presynaptic terminals and processes of recovery from vesicle depletion as a consequence of activity.

III.Several faculty members also have projects that relate their fundamental research interests to mechanisms underlying diseases of the human nervous system.
 
  • Dr. Salvaterra is developing Drosophila models for Alzheimer’s and other degenerative diseases.
     
  • Dr. Lu is examining how alteration in the neural stem cell decision to proliferate or differentiate controlled by ephrin/Eph receptor signaling may be involved in the earliest stages of tumorigenesis.
     
  • Dr. Tomoda is investigating possible connections between genes involved in membrane cycling and autophagy, and several diseases including Huntington’s and schizophrenia.
     
  • Dr. Barish, in collaboration with Karen Aboody, M.D. , (Hematology/HCT) and Carlotta Glackin, Ph.D. , is examining the molecular mechanisms of neural progenitor cell migration to glioma and tumors outside the brain, and targeting of these tumors with genetically-modified therapeutics using immortalized neural progenitor cells.
     
  • Dr. Glackin and her laboratory are investigating the molecular mechanisms of a bHLH transcription factor, TWIST, in regulating cellular invasiveness. Understanding these mechanisms has allowed her laboratory to develop novel genetically-modified therapeutics that interferes with TWIST function to competitively inhibit cellular invasion of tumor cells.

Neurosciences Faculty

Neurosciences Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • To say that myelofibrosis patients need more treatment options would be an understatement. The severely low platelet counts, known as thrombocytopenia, that are one of the hallmark symptoms of the disease can lead to chronic fatigue and weakness that not only damage quality of life but, ultimately, shorten life...
  • Patients with metastatic colorectal cancer often stop responding to the primary drugs used against the disease, leaving them with few options and little hope. Determined to increase those options, doctors and researchers at City of Hope are conducting two clinical trials that could lead to new treatments for pe...
  • Investigators working at City of Hope are making many significant inroads against many forms of cancer. To do that, they have to take a variety of approaches. Molecular oncology researchers focus on abnormal cancer-associated activity in a cell’s nucleus. One especially prominent factor in many breast and ovari...
  • In light of the new breast cancer screening guidelines, which call for women to have mammograms every other year from age 50 to 74, it’s more important than ever for women to understand their individual risk. On Monday, the U.S. Preventive Services Task force released new breast cancer screening guideline...
  • Cancer patients need, and deserve, more than medical care. They and their families need high-quality supportive care – that is, care that addresses their physical, emotional and spiritual well-being. Health care professionals increasingly understand this, but starting such programs from scratch isn’t easy...
  • Each year, City of Hope patients given another chance at life gather to pose for a picture like this one. Going on its 39th year, the celebration of patients free of blood cancers thanks to bone marrow or stem cell transplants has grown such that a photographer has to scale a cherry picker just to […]
  • Cancer patients who are participating in early-stage clinical trials need extra emotional and physical support due to their additional stress and often unique symptoms. Now an effort by researchers at City of Hope to create a model for such support has received a $6.8 million grant from the National Cancer Inst...
  • The need for improvements in treating malignant brain tumors has never been greater. Survival for many patients with these tumors are sometimes measured in just months. One reason that therapeutic options are limited is that traditional surgery is deemed too risky for many brain tumors, especially for those in ...
  • “Honestly, there’s nothing special about my story,” protested Daniel Samson, as he bounced Layla, his 3 1/2-year-old daughter, on his lap and put on a video for her to watch. “I just want to tell it for my own sake, and share it with other men who may be going through this chaos.” Samson spoke […]
  • As far back as he can remember, Jonathan Yamzon, M.D., wanted to be a doctor. “I knew it from the get-go,” he said, matter-of-factly. “I always envisioned it as the ideal; the supreme thing one could do with one’s life.” The youngest of six children, Yamzon was barely a toddler when his family moved to [&...
  • There’s never a “good” time for cancer to strike. With testicular cancer, the timing can seem particularly unfair. This disease targets young adults in the prime of life; otherwise healthy people unaccustomed to any serious illness, let alone cancer. And suddenly … “I can only imagine what they must...
  • Sure, a healthy lifestyle can lower a person’s risk, but the impact of specific actions is harder to tease out. Diet, exercise, tobacco use, nutritional supplements, alcohol consumption … How important are each of these factors, individually? Does strict adherence to (or rejection of) one get you a pass o...
  • Health care decisions are tough. They’re even tougher when you – or loved ones – have to make them without a plan or a conversation. National Healthcare Decisions Day, on April 16,  is a nationwide initiative to demystify the health care decision-making process and encourage families to start talking. Ult...
  • The statistics, direct from the American Cancer Society, are sobering: Cancer death rates among African-American men are 27 percent higher than for white men. The death rate for African-American women is 11 percent higher compared to white women. Hispanics have higher rates of cervical, liver and stomach cancer...
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...